Navigation Links
NOVAVAX Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/28/2011

tters, including expectations regarding revenue, operating expenses, use of cash, and clinical developments and anticipated milestones, including under the contract with HHS BARDA and our assessment of the prospects and results of our clinical trials and other activities related to our VLP vaccines, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. We caution readers not to place significant reliance on the forward-looking statements contained in this release. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates in pre-clinical or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even with positive data from pre-clinical studies or clinical trials, our product candidates may not prove to be safe and efficacious; decisions by regulatory agencies may delay or prevent our development programs or increase the costs of such programs; regulatory approval is needed before we can initiate clinical trials on our vaccines; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next subsequent influenza season, if at all; even with our contract with HHS BARDA, we may not have the resources to fully fund all the development activities associated with successfully developing and licensing our
'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , September 4, 2015 ... announces that Hutchison MediPharma Limited ("HMP"), its drug ... the second proof-of-concept ("POC") trial of fruquintinib in ... ("NSCLC") in China .  The ... in meeting the primary efficacy endpoint of progression ...
(Date:9/3/2015)... , Sept. 3, 2015 ... of New Drugs, Industry Changes and Emerging Opportunities ... human ovaries? Visiongain,s new study forecasts those pharmaceutical ... in that industry. You also explore trends, results, ... Our report gives revenue predictions to 2025 at ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... – Your New Guide to that Market, its R&D and ... want to assess the future of cancer-treating medicines? Visiongain,s new ... helping you stay ahead. There you discover financial data, R&D ... In our analysis you see forecasted sales ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine ... Mass., March 4 Decision Resources, one of the ... and healthcare issues, finds that second-line patient share of ... to 35.2 percent since last year,s report. Most of ...
... in Small, Ambulatory Physician PracticesSCHAUMBURG, Ill., March 3 ... Information Technology (CCHIT(R)), the federally recognized body for ... announced it will develop dermatology-specific functionality criteria beginning ... a response to an application from the American ...
Cached Medicine Technology:Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 3Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2
(Date:9/5/2015)... ... September 05, 2015 , ... As school supply lists continue to increase and budgets continue to ... their students. William Mattar Law Offices has found a way to help with their ... well as principals and superintendents as in past years. Because of that, the amount ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article ... the American Dental Association presented data showing that it is safe for pregnant women ... pregnant women that had undergone local anesthesia with a group that hadn’t, researchers were ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law ... De La Paz. , Schmidt National Law Group, a leading firm in mass-tort ... California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for ... new apparel. In an effort to assist the team, the Jones Agency, a locally ... drive to raise funds for the new uniforms. , As is so often the ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind is ... is quite common. Mold can grow anywhere - on carpet, clothing, food, paper, and ... excessive moisture and water in the home is key to preventing mold growth, which ...
Breaking Medicine News(10 mins):Health News:‘Pencils 4 Schools’ Campaign 2015 Exceeds Expectations from Previous Year 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4
... 22 Cambridge Research & Instrumentation, Inc. ... System at the 100th Annual Meeting of ... in Denver. The Vectra system is the ... for rapidly generating high-resolution cellular and tissue ...
... 22 Today in a House Foreign Affairs ... Obama Administration, U.S. Rep. Chris Smith (R-N.J.) asked ... to overturn other countries pro-life laws and if ... as including abortion.Secretary Clinton,s answered the latter question ...
... a grape-enriched diet prevent the downhill sequence of heart failure ... of Michigan Cardiovascular Center study suggests grapes may prevent heart ... come from a diet rich in fruits and vegetables. The ... occurring antioxidants turning on a protective process in the ...
... - Increases 2009 Guidance for Revenue and Earnings per ... 2009 Highlights:- Total revenue of $80.0 million; up 56.3% ... from fourth quarter 2008- Gross margin of 81.5% compared ... share was $(0.12); favorable to prior guidance of $(0.27) ...
... controversial birth-control drug , , WEDNESDAY, April 22 (HealthDay News) ... Food and Drug Administration said Wednesday that it will ... control pill without a doctor,s prescription. , In ... to the pill, also known as Plan B, to ...
... Halo Pharmaceutical, this week announced that ... from The Provident Bank to expand its ... held full-service, specialty pharmaceutical company. Halo provides ... and laboratory services to the pharmaceutical and ...
Cached Medicine News:Health News:CRi's New Vectra(TM) Platform Rapidly Analyzes Tissue Slides and Microarrays in Brightfield and Fluorescence 2Health News:FRC Action: Obama Administration Working to Overturn Pro-Life Laws in Other Countries 2Health News:Benefit of grapes may be more than skin deep 2Health News:Benefit of grapes may be more than skin deep 3Health News:NuVasive Reports First Quarter 2009 Financial Results 2Health News:NuVasive Reports First Quarter 2009 Financial Results 3Health News:NuVasive Reports First Quarter 2009 Financial Results 4Health News:NuVasive Reports First Quarter 2009 Financial Results 5Health News:NuVasive Reports First Quarter 2009 Financial Results 6Health News:NuVasive Reports First Quarter 2009 Financial Results 7Health News:NuVasive Reports First Quarter 2009 Financial Results 8Health News:NuVasive Reports First Quarter 2009 Financial Results 9Health News:NuVasive Reports First Quarter 2009 Financial Results 10Health News:NuVasive Reports First Quarter 2009 Financial Results 11Health News:NuVasive Reports First Quarter 2009 Financial Results 12Health News:NuVasive Reports First Quarter 2009 Financial Results 13Health News:NuVasive Reports First Quarter 2009 Financial Results 14Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank 2
... innovative proficiency testing solutions with outstanding customer ... API is one of the largest proficiency ... 12,000 laboratories enrolled. Here are just some ... Paperless Proficiency Testing, Free CME/CMLE ...
... Pefakit APC-R FVL is a new functional ... specificity for Activated Protein C Resistance caused ... In contrast to other commercially available methods, ... protein C or S, Lupus Anticoagulants, Elevated ...
... NIDEK YC-1800 is an advanced ophthalmic ... and output technologies, improved operability, fast ... compact design with versatility for combination ... the YC-1600 and adds several unique ...
The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
Medicine Products: